For eligible patients, Semaglutide GLP-1 injections offer a path toward better overall health, reduced weight, and a decreased risk of associated diseases, all while providing a well-tolerated and clinically proven treatment option
About the study The phase 3a, multicenter, randomized, double-blind, placebo- and active-controlled REDEFINE 1 trial enrolled 3,417 adults across 22 countries
Addressing Stigma and Promoting Positive Messaging Nearly 70% of people taking GLP-1 medication have been asked about their use of weight-loss medication
A different peptide (AHK-Cu), specifically designed for hair follicles
Exenatide is available in both short-acting (twice-daily, Byetta) and extended-release (once-weekly, Bydureon) formulations